Compare · RVMD vs VIR
RVMD vs VIR
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Vir Biotechnology Inc. (VIR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and VIR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $35.25B, about 21.8x VIR ($1.61B).
- RVMD has been more active in the news (15 items in the past 4 weeks vs 6 for VIR).
- RVMD has more recent analyst coverage (25 ratings vs 19 for VIR).
- Company
- Revolution Medicines Inc.
- Vir Biotechnology Inc.
- Price
- -
- -
- Market cap
- $35.25B
- $1.61B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 19
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Vir Biotechnology Inc.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Latest RVMD
- Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
- Officer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax
- Officer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax
- General Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax
- Officer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Revolution Medicines Inc.
Latest VIR
- Director Coughlin Timothy was granted 16,000 units of Common Stock (SEC Form 4)
- New insider Coughlin Timothy claimed no ownership of stock in the company (SEC Form 3)
- Vir Biotechnology Inc. filed SEC Form 8-K: Leadership Update
- Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
- Director Napolitano Janet sold $30,240 worth of shares (3,200 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 21,216 units (SEC Form 4)
- SVP, Chief Accounting Officer Sabatini Brent sold $3,582 worth of Common Stock (379 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 61,902 units (SEC Form 4)
- Director Sigal Charles Elliott was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)
- Director Napolitano Janet was granted 8,000 shares, increasing direct ownership by 49% to 24,416 units (SEC Form 4)
- Director More Robert J was granted 8,000 shares, increasing direct ownership by 20% to 48,656 units (SEC Form 4)
- Director Hatfield Jeffrey S. was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)